Your browser doesn't support javascript.
loading
Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor.
Shraga, Amit; Olshvang, Evgenia; Davidzohn, Natalia; Khoshkenar, Payam; Germain, Nicolas; Shurrush, Khriesto; Carvalho, Silvia; Avram, Liat; Albeck, Shira; Unger, Tamar; Lefker, Bruce; Subramanyam, Chakrapani; Hudkins, Robert L; Mitchell, Amir; Shulman, Ziv; Kinoshita, Takayoshi; London, Nir.
Afiliación
  • Shraga A; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Olshvang E; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Davidzohn N; Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Khoshkenar P; Program for Systems Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
  • Germain N; Maurice and Vivienne Wohl Institute for Drug Discovery, Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Shurrush K; Maurice and Vivienne Wohl Institute for Drug Discovery, Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Carvalho S; Maurice and Vivienne Wohl Institute for Drug Discovery, Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Avram L; Department of Chemical Research Support, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Albeck S; Structural Proteomics Unit, Department of Life Sciences Core Facilities, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Unger T; Structural Proteomics Unit, Department of Life Sciences Core Facilities, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Lefker B; Maurice and Vivienne Wohl Institute for Drug Discovery, Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot 76100, Israel; Pfizer, Research and Development, USA.
  • Subramanyam C; Maurice and Vivienne Wohl Institute for Drug Discovery, Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot 76100, Israel; Pfizer, Research and Development, USA.
  • Hudkins RL; Specialty Research & Development, Teva Pharmaceuticals, Inc., West Chester, PA 19380, USA.
  • Mitchell A; Program for Systems Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
  • Shulman Z; Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel.
  • Kinoshita T; Graduate School of Science, Osaka Prefecture University, Osaka 599-8531, Japan.
  • London N; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: nir.london@weizmann.ac.il.
Cell Chem Biol ; 26(1): 98-108.e5, 2019 01 17.
Article en En | MEDLINE | ID: mdl-30449673
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: MAP Quinasa Quinasa 7 / Inhibidores de Proteínas Quinasas / Simulación del Acoplamiento Molecular Límite: Animals / Humans Idioma: En Revista: Cell Chem Biol Año: 2019 Tipo del documento: Article País de afiliación: Israel
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: MAP Quinasa Quinasa 7 / Inhibidores de Proteínas Quinasas / Simulación del Acoplamiento Molecular Límite: Animals / Humans Idioma: En Revista: Cell Chem Biol Año: 2019 Tipo del documento: Article País de afiliación: Israel